PODXL and hepatocellular carcinoma: In particular, high PODXL expression has been associated with high-grade tumours, aggressive tumour phenotypes, and poor prognosis in breast cancer [15,54], colorectal cancer [19,55,56,57], gastric cancer [58,59,60], hepatocellular carcinoma [54,61], lung cancer including small cell lung carcinoma [62], and lung adenocarcinoma [63].